`

Working group 3

WG3 overall objectives

Working group 3 joins up clinical sites working on renal MRI, and will pave the way for clinical use of renal MRI by addressing the need for stronger evidence in patients. 

The standardised methods developed in WG1 and WG2 will be used in large prospective multicentre clinical studies aimed at providing additional evidence of biological and clinical validity (against histopathology and reference methods) and clinical utility (prognostic value) of MRI biomarkers in renal disease.


WG3 short-term aims

  • Prepare the ground for a large scale longitudinal multicentre study aimed at providing additional evidence of biological and clinical validity of MRI biomarkers in CKD (look for fundings, draw up minimum standards for sites to participate in multicentre trials)

  • Explore grant funding to further validate MRI biomarkers in ADPKD

  • Explore grant funding to validate MRI biomarkers in renal transplantation

  • Coordinate smaller scale studies on specific relevant disease areas

  • Add MRI to ongoing renal initiative


WG3 achievements

  • Publication of an open access special issue on MRI biomarkers in renal disease in the journal Nephrol Dial Transplant, including an editorial, a position paper and 4 review papers (ASL, BOLD, DWI, T1&T2 mapping) providing a picture of the state of the art and practical recommendations. The special issue is free to view and download.

  • Creation of an ADPKD task force ( task force page), joining together all WG3 participants actively working in ADPKD MRI

  • Creation of a renal transplantation task force ( task force page), joining together all WG3 participants actively working in MRI in renal transplantation

  • Creation of a study document repository, containing study documents from past/ongoing clinical studies involving renal MRI, which could be helpful for designing new study protocols

  • Renal MRI dissemination in the radiology/nephrology communities 

  • Renal MRI ongoing multicenter clinical trials:

Study Clinical area N. patients Study type
Main info Principal investigator/ Contact person
iBEAt DKD 500 T2D, 50 T1D  Prospective, Observational Link
Prof. Steven Sourbron
HEROIC DKD 500 Prospective, Observational Link
Dr Kieran Mccafferty
AFiRM CKD 450 Prospective, Observational Link
Prof. Nicholas Selby
EMPA_KIDNEY
MRI sub-study
CKD 60 Prospective, Interventional (Empagliflozin) Link
Prof. Richard Haynes
DWI for kidney cortical intersitial fibrosis prediction
Renal transplantation 250 Prospective, Observational
Prof Jean-Paul Vallee


  • Renal MRI ongoing single-center clinical trials 

    (For renal MRI studies performed in ADPKD or renal transplantation please visit the corresponding task force page)

Study Clinical area N. patients Study type
Main
info
Principal investigator/
Contact person
SUGAR Heart failure, Diabetes 105 Prospective, Interventional (Empagliflozin) Link
Prof. Naveed Sattar
AM-01 DKD 66 Prospective, Observational

Dr Seema Baid-Agrawal
Dr Paul Hockings
Advanced MRI for improved diagnosis and prediction of treatment response in Wilms’ tumour patient
Wilms' tumour 110 Prospective, Observational
Dr Chris Clark
Renal diffusion in CKD CKD 150 Prospective, Observational
Dr Jean-Paul Vallée
ReMARK Healthy volunteers 20 Prospective, Observational
Dr Anneloes de Boer
ReFINED CKD, hypertension, healthy volunteers 10/10/15 Prospective, Observational
Dr Anneloes de Boer
Role of digital pathology and MRI in the early detection of interstitial fibrosis in CKD
CKD (both native and transplanted kidneys) 75 Prospective, Observational
Dr Carlos Nicolau
Gender-BOLD CKD and controls 110 Prospective, Observational
Dr Menno Pruijm
Functional MRI in the diagnostics of diabetic nephropathy in patients with type 2 DM
DKD 90 Prospective, Observational
Dr Olivera Nikolic
ACH471-205
MRI sub-study
C3G -
IC-MPGN rare disease
7 Prospective, Interventional (ACH-0144471)
Link
Dr Anna Caroli
ROCKIES Diabetes 40 (T2D and healthy controls) Prospective, Interventional
(Ertugliflozin)
Link
Dr Daniel van Raalte
GCKD MRI sub-study
CKD 30 prospective, observational
Prof. Dr. K. U. Eckardt / Dr. Maurice Heimer
Improvement of diagnostics of myeloma specific renal changes by functional MRI-biomarkers
multiple myeloma
40 patients, 10 healthy volunteers prospective, observational
Dr Alexandra Ljimani
Renal pathologies in rheumatological diseases: Improvement of diagnostics using functional magnetic resonance imaging
Lupus 30 prospective, observational

Dr Alexandra Ljimani
Quantitative magnetization transfer MRI for evaluation of renal fibrosis
Renovascular disease 15 prospective, observational Link Prof. Lilach O. Lerman
Advanced diffusion imaging for management of renal cancer: oncologic control and renal functional reserve
Renal cancer 24 healthy controls, 150 renal mass patients  prospective, observational Link Dr Eric Sigmund
Dr Hersh Chandarana 







  • Renal MRI completed clinical trials 

    (For renal MRI studies performed in ADPKD or renal transplantation please visit the corresponding task force page)

Study Clinical area N. patients Study type
Main
info
Principal investigator/
Contact person
REMIND-CKD CKD 26 prospective, observational Link
Prof. Nicholas Selby
REMIND-AKI AKI 10 prospective, observational
Prof. Nicholas Selby
Effects of the SGLT-2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-Diabetic Subjects: A Randomized, Double-Blind, Placebo-Controlled Study Protocol.
healthy volunteers (non-diabetic subjects) 15 normal weight, 15 overweight, 15 obese
prospective, interventional (Empagliflozin) Link
Dr Menno Pruijm
Renal NCE-MRI in Healthy Volunteers
healthy volunteers 16 prospective, observational Link
Dr Anna Caroli
Renal DCE-MRI in healthy volunteers comparing two imaging sequences (FLASH/KWIC) and use of iohexol clearance as clinical reference test
healthy volunteers 10 prospective, observational
Dr Eli Eikefjord
Test-retest renal DCE-MRI in healthy volunteers and use of iohexol clearance as clinical reference test
healthy volunteers 20 prospective, observational
Dr Eli Eikefjord
Renal DCE-MRI in living kidney donors
Kidney donors 20 prospective, observational
Dr Eli Eikefjord
Renal pCASL Repeatability/Reproducibility Study
healthy volunteers 10 prospective, observational

Dr Doug Pendse
MRI in healthy volunteers
healthy volunteers 7 prospective, observational
Dr Isky Gordon
MRI reproducibility in healthy volunteers
healthy volunteers 16 prospective, observational
Dr Isky Gordon
MRI in paediatric CKD paediatric CKD 11 prospective, observational
Dr Isky Gordon
Reproducibility of Single Kidney GFR with DCE-MRI in healthy volunteers
healthy volunteers 34 prospective, observational

Dr Isky Gordon
DWI in healthy volunteers
healthy volunteers 10 prospective, observational
Dr Paul Summers
DCE-MRI in renal pathology
mixed renal pathology 30 prospective, observational
Dr Paul Summers
Renden resistant hypertension 75 prospective, observational
Dr Anneloes de Boer
EnCORED: renal artery and parenchymal changes after RDN
therapy resistant hypertension 96 prospective, interventional (RDN)
Dr Anneloes de Boer
Influence of RAAS inhibition; determine the influence of RAAS inhibition on kidney oxygenation
CKD, healthy volunteers 10 CKD patients, 5 healthy volunteers prospective, interventional (RAAS inhibitors)
Dr Anneloes de Boer
LauBOLD CKD, hypertension, healthy volunteers 224 prospective, observational
Dr Menno Pruijm
4R01DK093793-05: Longitudinal Changes in the Intra-Renal Oxygenation by BOLD MRI in patients with CKD
CKD, healthy 66 prospective, observational Link
Dr Pottumarthi Prasad
5R21DK079080-02: The intra-renal oxygenation in CKD as evaluated by BOLD-MRI 
CKD, healthy 45 cross-sectional, observational Link
Dr Pottumarthi Prasad
CKD Optimal Management with Binders and Nicotinamide
(COMBINE)
CKD 122 prospective, interventional (nicotinamide and lanthanum carbonate)
Link Dr Anand Srivastava


WG3 meetings

October 16th 2019, Nottingham, UK - WG3 session

October 4-5th 2018, Prague, Czech republic - WG3 yearly meeting (meeting page)

April 23rd 2018, Utrecht, The Netherlands - WG3 strategy meeting (meeting page)

October 13th 2017, Berlin, Germany - WG3 yearly meeting (meeting page)

July 13-14th 2017, Bergamo, Italy - WG3 kick-off meeting (meeting page)


WG3 contact information

If you need additional information, or in case you are interested in joining this effort, please contact the WG3 leads:

Dr Anna Caroli (contact)

Prof Nicholas Selby (contact)

Members

Working group 3 Lead: Dr. Anna Caroli

Working group 3 Vice-Lead: Dr. Nicholas Selby